← Back to Home

SurVaxM Brain Cancer Vaccine Misses Overall Survival Endpoint, Shows Efficacy Signal in Patients Aged 65 and Younger

A randomized controlled trial has brought both the promise of a glioblastoma vaccine and the limits of the evidence into focus: the overall survival difference was not statistically significant, while a prespecified younger population had better outcomes. Whether this signal can support further development still awaits a complete analysis and regulatory discussions.

By SURL BioNews

For patients with newly diagnosed glioblastoma, whether a new therapy can give them more time to live is the most pressing question. On October 7, MimiVax and Roswell Park Comprehensive Cancer Center announced results from the phase 2b SURVIVE trial of the cancer vaccine SurVaxM: survival data for the overall patient population favored the vaccine group but did not reach the statistical significance required for the primary endpoint; a clearer efficacy signal emerged in the prespecified population aged 65 and younger.

The study, conducted at 11 cancer centers in the United States, used a randomized, double-blind, placebo-controlled design and included 233 evaluable patients. According to Targeted Oncology's summary, participants were adults who had undergone tumor resection and had a Karnofsky performance status score of at least 70. They were assigned in a 3:2 ratio to SurVaxM or a saline placebo, with both groups receiving adjuvant temozolomide chemotherapy. SurVaxM is a peptide mimic vaccine administered by subcutaneous injection, designed to prompt the immune system to recognize cancer cells expressing the survivin protein and attack the tumor.

Median overall survival in the overall patient population was 22.8 months in the vaccine group and 20.3 months in the placebo group, a difference of 2.5 months. However, the hazard ratio for death was 0.75, with a 95% confidence interval of 0.54 to 1.03, which included 1, the value indicating no difference. After adjustment through stratification by MGMT and performance status, the p-value was 0.076, failing to cross the commonly used threshold of 0.05. This numerical difference therefore cannot currently be regarded as an established overall survival benefit.

Results in the younger population offer another lead for research. Among patients aged 65 and younger, median overall survival was 24.2 months versus 20.2 months, with a hazard ratio for death of 0.64, a 95% confidence interval of 0.44 to 0.93, and a p-value of 0.019. Progression-free survival results in the same population also favored the vaccine group, with a hazard ratio of 0.64 and a p-value of 0.018. However, the announcement did not disclose the number of patients in this subgroup, how multiple comparisons were controlled, or a test of the interaction between age and efficacy. Even though the analysis was prespecified, these results cannot establish age as a reliable criterion for selecting patients likely to benefit, or supersede the conclusion that the overall trial missed its primary endpoint.

The control group's performance also affects interpretation of the results. CancerNetwork noted that the placebo group's median overall survival of 20.3 months exceeded the historical benchmark of 16 months used in the trial design. The development team believes this made it more difficult for the two groups to show a statistically significant difference. However, historical benchmarks provide only background; whether the vaccine adds benefit must still be assessed against the concurrent randomized control group, and the available data are insufficient to clarify why survival was longer in the control group.

Regarding safety, rates of grade 3 or higher adverse events were 48% in the vaccine group and 46% in the placebo group, while serious adverse event rates were 25% and 21%, respectively. Neither group had any treatment-related deaths. In the vaccine group, 4% of patients discontinued treatment because of adverse events, with one case attributed to the study treatment. Injection-site reactions were mostly grade 1 or 2, but similar overall adverse event rates do not mean the vaccine is without risk, nor can all events be attributed to the vaccine.

MimiVax plans to discuss the results, breakthrough therapy designation, and a possible accelerated approval pathway with the U.S. Food and Drug Administration (FDA) in the coming months. These remain company plans, rather than decisions already made by the regulator. SurVaxM has not yet received marketing approval. The information released this time comes primarily from the developers' announcement, which also formed the basis of reports by two specialist oncology media outlets. Whether the subsequent complete data can confirm the extent of benefit among younger patients, and what kind of confirmatory studies will be needed, will determine the vaccine's next steps.

References

  1. Roswell Park Comprehensive Cancer Center
  2. MimiVax
  3. CancerNetwork
  4. Targeted Oncology